Novo Nordisk (NVO 1.85%), prior to now the early mover within the GLP-1 weight reduction drug area, has misplaced its edge as competitor Eli Lilly has come to dominate the marketplace. On the other hand, may Novo have an ace within the hollow with the just lately launched pill-based model of its flagship weight reduction drug, Wegovy?
As CEO Mike Doustdar famous in a contemporary interview, 80% of Wegovy capsule sufferers are new to weight reduction medication. This means the corporate is capitalizing on sufferers considering weight reduction remedy however who’ve been hesitant to take a look at such therapies of their injectable shape.
Does this alteration the tale for the out-of-favor identify amongst GLP-1 shares? Let’s in finding out.
Symbol supply: Getty Photographs.
Wegovy capsule: a silver bullet for Novo Nordisk?
Introduced in January, the Wegovy capsule generated $355 million in gross sales all through the primary quarter.Opposite to preliminary issues that this capsule would cannibalize the corporate’s current marketplace percentage, Novo seems to be increasing the overall addressable marketplace with its release.
That isn’t all. As Jamey Millar, govt vp of Novo Nordisk’s U.S. operations, famous at the corporate’s Q1 convention name, the Wegovy capsule could also be gaining percentage from sufferers who prior to now used competing merchandise.
These days’s Trade
(-1.85%) $-0.81
Present Value
$42.94
Key Information Issues
Marketplace Cap
$145B
Day’s Vary
$42.86 – $44.19
52wk Vary
$35.12 – $81.44
Quantity
446.7K
Avg Vol
16.2M
Gross Margin
81.84%
Dividend Yield
4.19%
What this implies for the undergo case
To start with, you might imagine that Novo’s newest edge will briefly disappear as neatly. In any case, again in April, Eli Lilly introduced its personal pill-based GLP-1, orforglipron, advertised as Foundayo. On the other hand, up to now, Foundayo has but to achieve a lot traction. Consequently, Novo Nordisk simply raised its 2026 steering, in line with the expectancy that Foundayo’s release is not going to have an effect on additional enlargement for the Wegovy capsule.
Even though the Wegovy capsule is helping to force handiest better-than-expected effects shifting ahead, it would nonetheless have a large have an effect on on Novo’s long run inventory value. With stocks buying and selling underneath 13 occasions ahead income, buyers expect the corporate’s income to stay declining. On the other hand, if declines flatten or Novo returns to a wave of general enlargement, this may spark a rebound for the pharmaceutical inventory, which has fallen by way of over 40% prior to now 12 months.
Thomas Niel has no place in any of the shares discussed. The Motley Idiot has positions in and recommends Eli Lilly. The Motley Idiot recommends Novo Nordisk. The Motley Idiot has a disclosure coverage.
